NCT06828393View on ClinicalTrials.gov

A Phase 1 Study of S-1117

PHASE1RecruitingINTERVENTIONAL

Enrollment

96

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Healthy Volunteer

Interventions

DRUG

S-1117

S-1117 via subcutaneous or intravenous administration.

OTHER

Placebo

Placebo via subcutaneous or intravenous administration.

Trial Locations (1)

5000

RECRUITING

CMAX Clinical Research, Adelaide

Sponsors

Collaborators (1)

Avance Clinical Pty Ltd.

All Listed Sponsors

collaborator

Avance Clinical Pty Ltd.

INDUSTRY

lead

Seismic Therapeutic AU Pty Ltd

INDUSTRY